3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Transitional Cell
29
Urinary Bladder Neoplasms
26
Carcinoma, Renal Cell
22
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
7
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Ureteral Neoplasms
5
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Merkel Cell
5
Urethral Neoplasms
4
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Small Cell Lung Carcinoma
3
Kidney Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Penile Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lung Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Turcot syndrome
1
Testicular Neoplasms
1
Interventions
Sunitinib
4
avelumab
2
Nutrition Assessment
2
Blood Specimen Collection
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Specimen Handling
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Kidney Diseases
×
avelumab
×
Genitourinary
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts